A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models-Reference-Cited by-同舟云学术

A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models

Published:2021-09-15 Issue:611 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Lightcap Eric S.¹^ORCID,Yu Pengfei²^ORCID,Grossman Stephen¹,Song Keli¹,Khattar Mithun¹,Xega Kristina¹^ORCID,He Xingyue¹,Gavin James M.¹,Imaichi Hisashi¹^ORCID,Garnsey James J.¹^ORCID,Koenig Erik¹^ORCID,Zhang Hongru²,Lu Zhen²,Shah Pooja¹^ORCID,Fu Yu¹^ORCID,Milhollen Michael A.¹^ORCID,Hatton Beryl A.³^ORCID,Riceberg Jessica¹,Shinde Vaishali¹^ORCID,Li Cong¹,Minissale James¹^ORCID,Yang Xiaofeng¹^ORCID,England Dylan¹^ORCID,Klinghoffer Richard A.³,Langston Steve¹^ORCID,Galvin Katherine¹,Shapiro Gary¹,Pulukuri Sai M.¹,Fuchs Serge Y.²^ORCID,Huszar Dennis¹^ORCID

Affiliation:

1. Millennium Pharmaceuticals Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA 02139, USA.

2. Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

3. Presage Biosciences Inc., Seattle, WA 98109, USA.

Abstract

TAK-981, a first-in-class small-molecule SUMOylation inhibitor, activates type I interferon signaling to promote antitumor immune responses in mice.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference53 articles.

1. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors